Lixisenatide

Lixisenatide (formerly known as AVE0010) is a short-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is a synthetic analog of exendin-4 (originally derived from the Gila monster lizard's saliva). As a prandial GLP-1 receptor agonist, its primary mechanism of action includes slowing gastric emptying and stimulating glucose-dependent insulin secretion, which makes it particularly effective for controlling postprandial blood glucose levels in patients with type 2 diabetes.